Pathologic complete response to preoperative sequential foxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer

Clinical Breast Cancer

Volumn 10, Issue 1, 2010, Pages 40-45

  Chumsri, Saranya ^a   Jeter, Stacie ^b   Jacobs, Lisa K ^b   Nassar, Hind ^b   Armstrong, Deborah K ^b   Emens, Leisha A ^b   Fetting, John H ^b   Lange, Julie R ^b   Riley, Carol ^b   Tsangaris, Theodore N ^b   Wolff, Antonio C ^b   Zellars, Richard ^b   Zhang, Zhe ^b   Stearns, Vered ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Monoclonal antibody; Neoadjuvant therapy; Primary chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; PREOPERATIVE CARE; RETROSPECTIVE STUDY; SIDE EFFECT; THERAPY DELAY; TREATMENT RESPONSE;

EID: 76949095183     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.005     Document Type: Article

References (37)

1. Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erb-Brelated gene encoding a 185,000-Mr tumour antigen. Nature 1984; 312:513-516
2. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37(suppl 4):S3-8.
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-137
4. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-2648
5. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14:737-744
6. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-726
7. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792
8. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as firstline therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21:2889-2895
9. Chia S, Clemons M, Martin LA, et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006; 24:2773-2778
10. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:1800-1808
11. Jahanzeb M, Mortimer JE, Yunus F, et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 2002; 7:410-417
12. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23:4265-4274
13. O'Shaughnessy J, Vukelja SJ, Marsland T, et al. Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. Clin Breast Cancer 2002; 3(suppl 1):17-20.
14. Pegram MD, Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptorenhanced chemosensitivity. Semin Oncol 1999; 26:89-95.
15. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24:2786-2792
16. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39-51.
17. Briest S, Stearns V. Advances in the adjuvant and neoadjuvant treatment of breast cancer. Womens Health (Lond Engl) 2007; 3:325-339
18. Bullock K, Blackwell K. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist 2008; 13:515-525
19. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684
20. Perez EA, Suman VJ, Davidson N, et al. NCCTG N9831, May 2005 update. Paper presented at: the 45th annual meeting of the American Society of Clinical Oncology; May 16, 2005; Orlando, FL; May 16, 2005.
21. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007; 369:29-36.
22. Slamon D, Eiermann W, Robert N. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her-2neu positive early breast cancer patients. Paper presented at: the 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX; December 14-17, 2006.
23. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008; 14:14-24.
24. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17:460-469
25. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23:3676-3685
26. Dawood S, Gonzalez-Angulo AM, Peintinger F, et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer 2007; 110:1195-1200
27. Guarneri V, Frassoldati A, Piacentini F, et al. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial). Clin Breast Cancer 2008; 8:192-194
28. Coudert BP, Largillier R, Arnould L, et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 2007; 25:2678-2684
29. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006; 24:1940-1949.
30. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003; 21:46-53.
31. Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006; 24:1831-1838
32. Telli ML, Hunt SA, Carlson RW, et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007; 25:3525-3533
33. Collins ED, Moore CP, Clay KF, et al. Can women with early-stage breast cancer make an informed decision for mastectomy? J Clin Oncol 2009; 27:519-525
34. Throckmorton AD, Esserman LJ. When informed, all women do not prefer breast conservation. J Clin Oncol 2009; 27:484-486
35. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354:809-820
36. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005; 23:5983-5992
37. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358:1663-1671